ProQR Therapeutics N.V.

1.95 USD
+0.01 (+0.52%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

ProQR Therapeutics N.V. stock is up 4.84% since 30 days ago. The next earnings date is May 31, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 40% of the previous 9 May’s closed higher than April. 67% of analysts rate it a buy.

About ProQR Therapeutics N.V.

ProQR Therapeutics N.V. engages in the discovery and development of RNA-based therapeutics. It is primarily developing sepofarsen that is in phase II/III illuminate trial for treating leber's congenital amaurosis 10 disease. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University.

  • Chardan Capital
    Fri May 10, 10:13
  • HC Wainwright & Co.
    Fri May 10, 08:20
  • Citigroup
    Thu Apr 18, 11:57